Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.66 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29395810 | 1.00 | OPRD1 (0.66) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL30620560 | 1.00 | OPRD1 (0.66) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL28468334 | 0.89 | OPRM1 (0.62) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL29416620 | 0.85 | OPRD1 (0.78) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL547917 | 0.85 | OPRD1 (0.78) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL28470432 | 0.84 | OPRD1 (0.63) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL10243104 | 0.84 | OPRM1 (0.65) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL3475523 | 0.83 | OPRD1 (0.88) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Morphine SCHEMBL28712434 | 0.83 | OPRD1 (0.78) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Codeine SCHEMBL4730550 | 0.82 | OPRD1 (0.72) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165022-A1 | Pharmaceutical Formulation | KLARIA PHARMA HOLDING AB (SE) | 2024-05-23 | — | — | US | claimed |
| US-11904049-B2 | Pharmaceutical formulation | KLARIA PHARMA HOLDING AB (SE) | 2024-02-20 | — | — | US | claimed |
| US-20230063876-A1 | Virus-Like Particle Vaccines for Opioid Drugs | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2023-03-02 | — | — | US | claimed |
| US-20220160618-A1 | Pharmaceutical Formulation | KLARIA PHARMA HOLDING AB (SE) | 2022-05-26 | — | — | US | claimed |
| US-11219600-B2 | Pharmaceutical formulation | KLARIA PHARMA HOLDING AB (SE) | 2022-01-11 | — | — | US | claimed |
| EP-3932399-A1 | PHARMACEUTICAL FORMULATION | Klaria Pharma Holding AB (SE) | 2022-01-05 | — | — | EP | claimed |
| EP-3634377-B1 | PHARMACEUTICAL FORMULATION | KLARIA PHARMA HOLDING AB (SE) | 2021-07-21 | — | — | EP | claimed |
| US-20200246253-A1 | PHARMACEUTICAL FORMULATION | KLARIA PHARMA HOLDING AB (SE) | 2020-08-06 | — | — | US | claimed |
| EP-3634377-A1 | PHARMACEUTICAL FORMULATION | Klaria Pharma Holding AB (SE) | 2020-04-15 | — | — | EP | claimed |
| CN-110831575-A | Pharmaceutical preparation | 卡里亚制药控股有限公司 | 2020-02-21 | — | — | CN | claimed |
| EP-3560484-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G.L. Pharma GmbH (AT) | 2019-10-30 | — | — | EP | claimed |
| EP-3423034-B1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G L PHARMA GMBH (AT) | 2019-07-10 | — | — | EP | claimed |
| WO-2018224674-A9 | PHARMACEUTICAL FORMULATION | KLARIA PHARMA HOLDING AB (SE) | 2019-03-21 | — | — | WO | claimed |
| WO-2018224674-A1 | PHARMACEUTICAL FORMULATION | KLARIA PHARMA HOLDING AB (SE) | 2018-12-13 | — | — | WO | claimed |
| EP-3210596-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G.L. Pharma GmbH (AT) | 2017-08-30 | — | — | EP | claimed |
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ENALARE THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137670-A1 | SUSTAINED RELEASE DRUG DELIVERY SYSTEMS AND RELATED METHODS | DURECT CORP (US) | 2026-05-21 | — | — | US | disclosed |
| US-20150098983-A1 | Methods and Compositions for Treating Withdrawal Syndromes Using Non-Sedative Dexmedetomidine Transdermal Compositions | TEIKOKU PHARMA USA, INC. | 2015-04-09 | — | — | US | disclosed |
| WO-2015036734-A1 | SYNERGISTIC COMBINATION OF ANALGESIC DRUGS | UCL BUSINESS PLC (GB) | 2015-03-19 | — | — | WO | disclosed |
| CN-204147375-U | Be designed for the aerosol generation equipment producing condensation aerosol | NICOTINE TECHNOLOGY INC E | 2015-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246253-A1 | PHARMACEUTICAL FORMULATION | OGFR, OPRL1, OPRM1 | OPRD1 5/4885OPRM1 3/4885OPRK1 4/4885 |
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ADRA2B, ADRB1, ADRB2 | OPRD1 4/4885OPRM1 6/4885OPRK1 7/4885 |
| US-20260137670-A1 | SUSTAINED RELEASE DRUG DELIVERY SYSTEMS AND RELATED METHODS | SLC10A2, OPRK1, HBB | OPRD1 63/4885OPRM1 5/4885OPRK1 2/4885 |
| US-20150098983-A1 | Methods and Compositions for Treating Withdrawal Syndromes Using Non-Sedative Dexmedetomidine Transdermal Compositions | CRH, OPRD1, ADRA2C | OPRD1 2/4885OPRM1 44/4885OPRK1 4/4885 |
| US-11219600-B2 | Pharmaceutical formulation | OGFR, OPRL1, OPRM1 | OPRD1 5/4885OPRM1 3/4885OPRK1 4/4885 |
| US-20220160618-A1 | Pharmaceutical Formulation | OGFR, OPRL1, OPRM1 | OPRD1 5/4885OPRM1 3/4885OPRK1 4/4885 |
| US-11904049-B2 | Pharmaceutical formulation | OGFR, OPRL1, OPRM1 | OPRD1 5/4885OPRM1 3/4885OPRK1 4/4885 |
| US-20240165022-A1 | Pharmaceutical Formulation | OGFR, OPRL1, OPRM1 | OPRD1 5/4885OPRM1 3/4885OPRK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.